28183348|t|Optimized creation of glioblastoma patient derived xenografts for use in preclinical studies
28183348|a|Glioblastoma multiforme (GBM) is the most common and lethal brain tumor in adults, highlighting the need for novel treatment strategies. Patient derived xenografts (PDX) represent a valuable tool to accomplish this task. PDX were established by implanting GBM tissue subcutaneously. Engraftment success was compared between NMRI Foxn1(nu) and NOD / SCID as well as between fresh and cryopreserved tissue. Established PDX were analyzed histologically and molecularly. Five PDX were experimentally treated with different drugs to assess their potential for preclinical drug testing. Establishment of PDX was attempted for 36 consecutive GBM cases with an overall success rate of 22.2% in NMRI Foxn1(nu) mice. No difference was observed between fresh or cryopreserved (20-1057 days) tissue in direct comparison (n = 10 cases). Additionally, engraftment was better in NOD / SCID mice (38.8%) directly compared to NMRI Foxn1(nu) mice (27.7%) (n = 18 cases). Molecular data and histology of the PDX compare well to the primary GBM. The experimental treatment revealed individual differences in the sensitivity towards several clinically relevant drugs. The use of vitally frozen GBM tissue allows a more convenient workflow without efficiency loss. NOD / SCID mice appear to be better suited for initial engraftment of tumor tissue compared to NMRI Foxn1(nu) mice.
28183348	10	18	creation	T052	C1706214
28183348	22	34	glioblastoma	T191	C0017636
28183348	35	61	patient derived xenografts	T050	C4050317
28183348	73	92	preclinical studies	T062	C0013206
28183348	93	116	Glioblastoma multiforme	T191	C1621958
28183348	118	121	GBM	T191	C1621958
28183348	135	141	common	T081	C0205214
28183348	146	152	lethal	T033	C3151529
28183348	153	164	brain tumor	T191	C0006118
28183348	168	174	adults	T100	C0001675
28183348	202	207	novel	T080	C0205314
28183348	208	217	treatment	T061	C0087111
28183348	218	228	strategies	T041	C0679199
28183348	230	256	Patient derived xenografts	T050	C4050317
28183348	258	261	PDX	T050	C4050317
28183348	263	272	represent	T052	C1882932
28183348	308	312	task	T057	C3540678
28183348	314	317	PDX	T050	C4050317
28183348	338	348	implanting	T061	C0021107
28183348	349	352	GBM	T191	C1621958
28183348	353	359	tissue	T024	C0040300
28183348	360	374	subcutaneously	T033	C1736929
28183348	376	387	Engraftment	T039	C0301944
28183348	388	395	success	T033	C1272702
28183348	400	408	compared	T052	C1707455
28183348	417	431	NMRI Foxn1(nu)	T015	C1513846
28183348	436	439	NOD	T015	C0085243
28183348	442	446	SCID	T015	C0085112
28183348	466	471	fresh	T031	C2827486
28183348	476	489	cryopreserved	T059	C0010405
28183348	490	496	tissue	T024	C0040300
28183348	498	509	Established	T080	C0443211
28183348	510	513	PDX	T050	C4050317
28183348	519	527	analyzed	T062	C0936012
28183348	528	542	histologically	T169	C0205462
28183348	547	558	molecularly	T080	C1521991
28183348	565	568	PDX	T050	C4050317
28183348	574	588	experimentally	T080	C1517586
28183348	589	596	treated	T169	C1522326
28183348	602	611	different	T080	C1705242
28183348	612	617	drugs	T121	C0013227
28183348	621	627	assess	T058	C0184514
28183348	634	643	potential	T080	C3245505
28183348	648	672	preclinical drug testing	T062	C1512070
28183348	691	694	PDX	T050	C4050317
28183348	699	708	attempted	T051	C1516084
28183348	716	727	consecutive	T080	C1707491
28183348	728	731	GBM	T191	C1621958
28183348	732	737	cases	T096	C0681850
28183348	746	753	overall	T080	C1561607
28183348	754	761	success	T080	C0679864
28183348	762	766	rate	T081	C1521828
28183348	779	798	NMRI Foxn1(nu) mice	T015	C1513846
28183348	800	813	No difference	T033	C3842396
28183348	818	826	observed	T169	C1441672
28183348	835	840	fresh	T031	C2827486
28183348	844	857	cryopreserved	T059	C0010405
28183348	867	871	days	T079	C0439228
28183348	873	879	tissue	T024	C0040300
28183348	890	900	comparison	T052	C1707455
28183348	909	914	cases	T096	C0681850
28183348	931	942	engraftment	T039	C0301944
28183348	957	960	NOD	T015	C0085243
28183348	963	972	SCID mice	T015	C0085112
28183348	990	998	compared	T052	C1707455
28183348	1002	1021	NMRI Foxn1(nu) mice	T015	C1513846
28183348	1038	1043	cases	T096	C0681850
28183348	1046	1055	Molecular	T080	C1521991
28183348	1056	1060	data	T078	C1511726
28183348	1065	1074	histology	T169	C4048239
28183348	1082	1085	PDX	T050	C4050317
28183348	1086	1093	compare	T052	C1707455
28183348	1106	1113	primary	T080	C0205225
28183348	1114	1117	GBM	T191	C1621958
28183348	1123	1135	experimental	T080	C1517586
28183348	1136	1145	treatment	T061	C0087111
28183348	1146	1154	revealed	T080	C0443289
28183348	1166	1177	differences	T080	C1705242
28183348	1185	1196	sensitivity	T169	C0332324
28183348	1205	1212	several	T081	C0443302
28183348	1213	1223	clinically	T080	C0205210
28183348	1224	1232	relevant	T080	C2347946
28183348	1233	1238	drugs	T121	C0013227
28183348	1266	1269	GBM	T191	C1621958
28183348	1270	1276	tissue	T024	C0040300
28183348	1291	1301	convenient	T080	C3831015
28183348	1302	1310	workflow	T077	C1710679
28183348	1319	1329	efficiency	T081	C0013682
28183348	1336	1339	NOD	T015	C0085243
28183348	1342	1351	SCID mice	T015	C0085112
28183348	1391	1402	engraftment	T039	C0301944
28183348	1406	1411	tumor	T191	C0027651
28183348	1412	1418	tissue	T024	C0040300
28183348	1419	1427	compared	T052	C1707455
28183348	1431	1450	NMRI Foxn1(nu) mice	T015	C1513846